Quanterix Corp (NASDAQ:QTRX)
| Market Cap | $93.06M-72.1% |
| Revenue (ttm) | $148.15M+14.9% |
| Net Income | -$111.18M-16.2% |
| EPS | -$2.36-1.3% |
| Shares Out | 47.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,055,963 |
| Open | $1.96 |
| Previous Close | $2.03 |
| Day's Range | $1.79 - $2.03 |
| 52-Week Range | $1.76 - $8.77 |
| Beta | 1.04 |
| Analysts | Buy |
| Price Target | $3.00(+53.06%) |
| Earnings Date | Mar 2, 2027 |
About QTRX
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
Analyst consensus
1 firm rating QTRX in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 2, 2027Earnings report
$QTRX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in QTRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by QTRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
QTRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
QTRX Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New QTRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to QTRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in QTRX
| VTIVanguard Morningstar Total Stock Market ETF | $2.87M |
| IWMiShares Russell 2000 ETF | $2.30M |
| VXFVanguard Extended Market ETF | $1.45M |
| IWNiShares Russell 2000 Value ETF | $795.29K |
| VTWOVanguard Russell 2000 ETF | $729.72K |
| IBBiShares Biotechnology ETF | $627.58K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from QTRX’s recent data — informational, not investment advice
What’s Behind the Score
News check: CEO departure is offset by business expansion (Alzheimer's testing access, partnerships) and Q3 earnings, showing mixed signals with underlying operational progress.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.64% |
| NIFE | Direxion Fallen Knives ETF | 0.34% |
| FESC | First Eagle Small Cap Equity ETF | 0.19% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.14% |
| IBB | iShares Biotechnology ETF | 0.01% |
| VHT | Vanguard Health Care ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
